Information Provided By: 
Fly News Breaks for August 23, 2019
RTRX
Aug 23, 2019 | 07:29 EDT
Barclays analyst Gena Wang said the topline miss in the FORT Phase 3 trial was "an obvious disappointment," but also "not totally unexpected." Given no signs of clinical benefit, the Fosmet program is expected to be discontinued, said Wang, who is now looking toward the sparsentan data in focal segmental glomerulosclerosis in the first half of 2021. Following the Fosmet news, Wang lowered her price target on Retrophin shares to $20 from $36 and keeps an Overweight rating on the stock.
News For RTRX From the Last 2 Days
There are no results for your query RTRX
